Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: A post hoc analysis of three studies of children aged 2 to 6 years

Clinical Therapeutics

Volumn 31, Issue 10, 2009, Pages 2140-2147

  Block, Stan L ^a   Toback, Seth L ^b   Yi, Tingting ^b   Ambrose, Christopher S ^b  

^a Kentucky Pediatric Research Institute   (United States)

^b MEDIMMUNE   (United States)

Author keywords

children; efficacy; live attenuated influenza vaccine (LAIV); single dose

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE; PLACEBO;

AGE DISTRIBUTION; ANOREXIA; ARTICLE; CHILD; CHILL; CLINICAL TRIAL; COUGHING; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG TOLERABILITY; HUMAN; INFECTION CONTROL; INFLUENZA; IRRITABILITY; LETHARGY; MYALGIA; NOSE CONGESTION; OTITIS MEDIA; OUTCOME ASSESSMENT; POST HOC ANALYSIS; PRESCHOOL CHILD; REVACCINATION; RHINORRHEA; SEASONAL VARIATION; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; SORE THROAT; TREATMENT DURATION; VOMITING;

CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ENDPOINT DETERMINATION; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; KAPLAN-MEIERS ESTIMATE; MALE; PROSPECTIVE STUDIES; VACCINES, ATTENUATED;

EID: 71549134904     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.09.014     Document Type: Article

References (9)

1. Fiore A.E., Shay D.K., Broder K., et al., Centers for Disease Control and Prevention. Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 [published correction appears in MMWR Recomm Rep. 2009;58:896-897]. MMWR Recomm Rep. 58 (2009) 1-52
2. Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among children aged 6-23 months-United States, 2005-06 influenza season. MMWR Morb Mortal Wkly Rep. 56 (2007) 959-963
3. Jackson L.A., Neuzil K.M., Baggs J., et al. Compliance with the recommendations for 2 doses of trivalent inactivated influenza vaccine in children less than 9 years of age receiving influenza vaccine for the first time: A Vaccine Safety Datalink study. Pediatrics 118 (2006) 2032-2037
4. Bracco Neto H., Farhat C.K., Tregnaghi M.W., et al., D153-P504 LAIV Study Group. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 28 (2009) 365-371
5. Belshe R.B., Mendelman P.M., Treanor J., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 338 (1998) 1405-1412
6. Belshe R.B., Gruber W.C., Mendelman P.M., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 136 (2000) 168-175
7. Tam J.S., Capeding M.R., Lum L.C., et al., Pan-Asian CAIV-T Pediatric Efficacy Trial Network. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26 (2007) 619-628
8. FluMist® [prescribing information] (2009), MedImmune, LLC, Gaithersburg, Md
9. Belshe R.B., Ambrose C., and Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 26 Suppl 4 (2008) D10-D16